These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36341885)

  • 1. Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease.
    Mann JFE; Joseph P; Gao P; Pais P; Tyrwhitt J; Xavier D; Dans T; Jaramillo PL; Gamra H; Yusuf S;
    Kidney Int; 2023 Feb; 103(2):403-410. PubMed ID: 36341885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
    Goicoechea M; de Vinuesa SG; Quiroga B; Verde E; Bernis C; Morales E; Fernández-Juárez G; de Sequera P; Verdalles U; Delgado R; Torres A; Arroyo D; Abad S; Ortiz A; Luño J
    Cardiovasc Drugs Ther; 2018 Jun; 32(3):255-263. PubMed ID: 29943364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD: An Individual Participant Data Meta-Analysis.
    Sepanlou SG; Mann JFE; Joseph P; Pais P; Gao P; Sharafkhah M; Roshandel G; Yusuf S; Malekzadeh R;
    Clin J Am Soc Nephrol; 2023 Nov; 18(11):1408-1415. PubMed ID: 37550842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Mann JFE; Fonseca V; Mosenzon O; Raz I; Goldman B; Idorn T; von Scholten BJ; Poulter NR
    Circulation; 2018 Dec; 138(25):2908-2918. PubMed ID: 30566006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
    Carrero JJ; Varenhorst C; Jensevik K; Szummer K; Lagerqvist B; Evans M; Spaak J; Held C; James S; Jernberg T
    Kidney Int; 2017 Jan; 91(1):216-226. PubMed ID: 27865441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
    Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
    Majithia A; Bhatt DL; Friedman AN; Miller M; Steg PG; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Budoff M; Preston Mason R; Tardif JC; Boden WE; Ballantyne CM
    Circulation; 2021 Nov; 144(22):1750-1759. PubMed ID: 34706555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial.
    Tuttle KR; Dworkin LD; Henrich W; Greco BA; Steffes M; Tobe S; Shapiro JI; Jamerson K; Lyass A; Pencina K; Massaro JM; D'Agostino RB; Cutlip DE; Murphy TP; Cooper CJ
    Clin J Am Soc Nephrol; 2016 Jul; 11(7):1180-1188. PubMed ID: 27225988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
    Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
    J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
    Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial.
    Jardine MJ; Ninomiya T; Perkovic V; Cass A; Turnbull F; Gallagher MP; Zoungas S; Lambers Heerspink HJ; Chalmers J; Zanchetti A
    J Am Coll Cardiol; 2010 Sep; 56(12):956-65. PubMed ID: 20828648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The difference between cystatin C- and creatinine-based eGFR is associated with adverse cardiovascular outcome in patients with chronic kidney disease.
    Kim H; Park JT; Lee J; Jung JY; Lee KB; Kim YH; Yoo TH; Kang SW; Choi KH; Oh KH; Ahn C; Han SH;
    Atherosclerosis; 2021 Oct; 335():53-61. PubMed ID: 34571286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Hijazi Z; Alexander JH; Li Z; Wojdyla DM; Mehran R; Granger CB; Parkhomenko A; Bahit MC; Windecker S; Aronson R; Berwanger O; Halvorsen S; de Waha-Thiele S; Sinnaeve P; Darius H; Storey RF; Lopes RD
    Circulation; 2021 Mar; 143(12):1215-1223. PubMed ID: 33461308
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Ikeme JC; Pergola PE; Scherzer R; Shlipak MG; Benavente OR; Peralta CA
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1040-1047. PubMed ID: 28446537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease.
    Wolfe R; Wetmore JB; Woods RL; McNeil JJ; Gallagher H; Roderick P; Walker R; Nelson MR; Reid CM; Shah RC; Ernst ME; Lockery JE; Tonkin AM; Abhayaratna WP; Gibbs P; Wood EM; Mahady SE; Williamson JD; Donnan GA; Cloud GC; Murray AM; Polkinghorne KR
    Kidney Int; 2021 Feb; 99(2):466-474. PubMed ID: 32920022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.